Can Gabapentin Induce Parkinsonism?
Yes, gabapentin can induce parkinsonism, and clinicians should be aware of this risk when prescribing this medication, particularly in older adults or those with pre-existing neurological conditions.
Evidence for Gabapentin-Induced Parkinsonism
The association between gabapentin and parkinsonism is supported by robust pharmacoepidemiologic evidence. A 2023 case-crossover study using Japanese electronic medical records demonstrated that gabapentin exposure was associated with a 2.12-fold increased risk (95% CI, 1.73-2.61) of parkinsonism and related movement disorders 1. This finding remained consistent across multiple sensitivity analyses, strengthening the causal inference.
Earlier pharmacovigilance data from the WHO database (VigiBase) analyzing over 5.6 million case reports found 4,881 parkinsonism reports associated with gabapentin, with a reporting odds ratio of 2.16 (95% CI, 2.10-2.23) 2. Notably, this signal persisted even after excluding other drugs known to induce parkinsonism, suggesting an independent effect.
Clinical Implications
What to Look For:
- Temporal relationship: Symptoms typically develop during active gabapentin therapy, with the hazard period identified as 90 days before symptom onset 1
- Movement disorder manifestations: Beyond classic parkinsonian features (tremor, rigidity, bradykinesia), gabapentin can cause ataxia, dyskinesia, and abnormal gait 3, 4
- Neurological side effects: The FDA label documents ataxia (12.5%), tremor (6.8%), coordination abnormalities (1.1%), and abnormal thinking (1.7%) in controlled trials 3
Critical Diagnostic Challenge:
The most important pitfall is distinguishing drug-induced parkinsonism (DIP) from unmasking of underlying idiopathic Parkinson's disease. While DIP is typically reversible upon drug discontinuation, some patients may have subclinical Parkinson's disease that becomes apparent with gabapentin exposure 5.
Key differentiating features:
- DIP: Typically bilateral, symmetric onset; no resting tremor; poor levodopa response
- Idiopathic PD: Asymmetric onset; resting tremor present; good levodopa response
- When uncertain: Consider DaTSCAN imaging to assess dopaminergic neuron integrity 5
Risk Stratification
The risk appears comparable to pregabalin (reporting odds ratio 2.43) and tramadol (adjusted odds ratio 2.04), suggesting a class effect among gabapentinoids 1, 2. The 2024 comprehensive review confirms dyskinesia as an atypical but recognized side effect of gabapentin 4.
Management Approach
- Monitor high-risk patients: Older adults, those with subtle motor symptoms, or family history of Parkinson's disease
- Document baseline motor function before initiating therapy
- If parkinsonism develops: Discontinue gabapentin and observe for symptom resolution over 3-6 months
- If symptoms persist: Consider DaTSCAN to evaluate for underlying neurodegenerative disease
- Alternative analgesics: Consider switching to medications with lower movement disorder risk if parkinsonism occurs
The FDA label does not specifically mention parkinsonism but documents multiple movement-related adverse effects including ataxia, tremor, and coordination abnormalities 3, which align with the broader spectrum of gabapentin-induced movement disorders identified in pharmacoepidemiologic studies.